Business Context and Reporting Period
Codexis, Inc. filed a Current Report on Form 8-K dated October 12, 2017. The filing discloses the entry into a Global Development, Option and License Agreement with Nestec Ltd. ("Nestlé Health Science") and Nestlé Health Science S.A. The agreement focuses on the development and commercialization of therapeutic enzyme product candidates for the treatment of hyperphenylalaninemia (HPA) and other inborn errors of amino acid metabolism.
Key Financial Metrics and Transaction Terms
This filing details a strategic collaboration rather than periodic financial results. Key financial terms of the agreement include:
- Upfront Payment: $14 million cash payment due within 30 days of the Effective Date.
- Option Exercise Payment: $3 million due within 60 days of the License Effective Date if the Option is exercised.
- Development and Approval Milestones: Up to $90 million.
- Sales-Based Milestones: Up to $250 million in the aggregate, contingent on net sales exceeding $1 billion in a single year.
- Royalties: Tiered royalties ranging from middle single digits to low double-digits of net sales.
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics for the Company.
Material Changes and Agreement Structure
The primary material change is the execution of the agreement granting Nestlé Health Science:
- An option to obtain an exclusive, worldwide, royalty-bearing, sublicensable license for products based on Codexis's therapeutic enzyme candidates for HPA.
- An exclusive right of first negotiation for enzymes discovered by Codexis for the prevention, diagnosis, treatment, and management of inborn errors of amino acid metabolism.
The initial compound under the agreement is CDX-6114. Nestlé Health Science may exercise the option after Codexis files an investigational new drug application and completes a Phase Ia study. The option expires 60 days after this trigger date if unexercised.
Outlook, Risks, and Contingencies
Development Responsibilities: Codexis is responsible for development activities, including the Phase Ia study, prior to the Option expiration or License Effective Date. Post-exercise, Nestlé Health Science assumes general responsibility for development.
Termination Rights: Nestlé Health Science may terminate for serious safety issues or at its convenience after the first anniversary. Codexis may terminate if Nestlé challenges the validity of Codexis's patents. Either party may terminate for uncured material breach or insolvency.
Risks: The filing includes standard forward-looking statement disclaimers. Risks include dependence on licensees, limited product portfolio, market reception of customer products, intellectual property challenges, and competition.
Investor Verification Checklist
- Verify the receipt of the $14 million upfront payment in the next quarterly financial report.
- Monitor the status of the investigational new drug application and Phase Ia study for CDX-6114 to determine the Option Trigger Date.
- Review the full text of the Global Development, Option and License Agreement filed as an exhibit to the 2017 Form 10-K for detailed exclusions and definitions.
- Assess the impact of the agreement on Codexis's cash runway and future revenue recognition policies.